About
Chris is the Chief Investment Officer of Syncona Investment Management Ltd. He is currently Chairman at five Syncona companies: NightStar Therapeutics (NASDAQ:NITE), Freeline Therapeutics, Gyroscope Therapeutics, Swan Therapeutics and Orbit Biomedical. He has been instrumental in their foundation and development including the acquisition of a gene therapy manufacturing platform from Rentschler Biotechnologie on behalf of Freeline. Previously, he was a partner of Apposite Capital LLP, a venture and growth capital healthcare investment company. Before Apposite, Chris had roles with Bioscience Managers Ltd, Neptune Investment Management Ltd and in the pharmaceutical industry. Chris holds a degree in Natural Sciences and a PhD in Organic Chemistry, both from the University of Cambridge.
Position in the VCSift Database
- • 2 investors at Syncona Partners LLP are tracked.
- • 2,531 investors hold the Chief Investment Officer role in VCSift. Chris Hollowood is one of them.
- • 8,972 investors are based in London, England, United Kingdom.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- London, UK
Contact Information
Find more investors like Chris
Search Investors